Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This project investigates the use of 4 weeks of 24 mg/day ondansetron as compared to placebo
on symptoms and brain functioning in patients with obsessive-compulsive disorder (OCD) and
tic disorders (TD). Patients will be randomized to receive ondansetron or placebo for 4
weeks, with MRI scans and symptom assessments occurring at baseline (before any drug) and at
the end of the 4 weeks. Patients will also be asked to come into the lab approximately 2
weeks into the trial for symptom assessments. The investigators hypothesize that after 4
weeks there will be greater reduction from baseline in sensory symptoms and the activation of
the insula and sensorimotor cortex compared for ondansetron as compared to placebo.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai NYU Langone Health